Society for Translational Oncology navigateright Episode
Aditya Bardia, MD, MPH,
Massachusetts General Hospital
Endocrine therapies, including aromatase inhibitors, represent the backbone of management of estrogen receptor-positive (ER+) breast cancer. However, despite endocrine therapy, a number of patients with ER+ breast cancer experience disease recurrence. Our group, along with others, has demonstrated the presence of acquired mutations in the ligand binding domain of estrogen receptor (ESR1), which can lead to constitutional activation of the estrogen receptor in the absence of ligand (estrogen) and thereby result in resistance to endocrine therapies.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.